Histone acetylation is an epigenetic modification that is unequivocally associated with increasing the propensity for gene transcription. As gene transcription is a crucial feature of long-lasting forms of memories, increments in histone acetylation generally favour learning and memory, and can be considered molecular memory aids.
Histone acetylation readily responds to neuronal activity in terms of neuronal depolarization and synaptic plasticity. So far, two pathways that mediate this response have been identified: the mitogen-activated protein kinase (MAPK) pathway and the dissociation of histone deacetylase 2 (HDAC2) from the chromatin.
A reduction in histone acetylation has been causally implicated in memory impairment associated with neurodegeneration, ageing and neurodevelopment disorders such as Rubinstein–Taybi syndrome. From these studies, a gain-of-function of HDAC2 and a loss-of-function of the histone acetyl transferase cyclic AMP-responsive element-binding (CREB)-binding protein (CBP) emerge as chief culprits.
The reduction of histone acetylation can be counteracted by the use of small molecule inhibitors of HDACs, so-called HDAC inhibitors (HDACis). Several HDACis have already been proven successful in rescuing cognitive deficits in animal models of neurodegeneration, Alzheimer's disease, ageing, and Rubinstein–Taybi syndrome, and might thus constitute a new template for pharmacological strategies against cognitive impairments.
Although their precise mode of action is still not fully characterized, HDACis might act through a process called epigenetic priming, a term originally used in cancer research. Epigenetic priming refers to a support-only mode of action of HDACis, whereby HDACis alone have little effect (on histone acetylation and gene transcription), but when applied in conjunction with ongoing treatments that increase gene expression programmes, HDACis further potentiate them.
concept of epigenetic priming can be applied to neuroplasticity as well, in that HDACs would further support neuronal activity-driven gene expression programmes while having little or no effect on genes with constant rates of transcription.
Long-lasting memories require specific gene expression programmes that are, in part, orchestrated by epigenetic mechanisms. Of the epigenetic modifications identified in cognitive processes, histone acetylation has spurred considerable interest. Whereas increments in histone acetylation have consistently been shown to favour learning and memory, a lack thereof has been causally implicated in cognitive impairments in neurodevelopmental disorders, neurodegeneration and ageing. As histone acetylation and cognitive functions can be pharmacologically restored by histone deacetylase inhibitors, this epigenetic modification might constitute a molecular memory aid on the chromatin and, by extension, a new template for therapeutic interventions against cognitive frailty.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Crick, F. Memory and molecular turnover. Nature 312, 101 (1984).
Levenson, J. M. & Sweatt, J. D. Epigenetic mechanisms in memory formation. Nature Rev. Neurosci. 6, 108–118 (2005). An excellent review that opened up the field of neuroepigenetics in 2005.
Bird, A. Perceptions of epigenetics. Nature 447, 396–398 (2007).
Kandel, E. R. The molecular biology of memory storage: a dialogue between genes and synapses. Science 294, 1030–1038 (2001).
Gräff, J., Kim, D., Dobbin, M. M. & Tsai, L. H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol. Rev. 91, 603–649 (2011).
Berndsen, C. E. & Denu, J. M. Catalysis and substrate selection by histone/protein lysine acetyltransferases. Curr. Opin. Struct. Biol. 18, 682–689 (2008).
Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev. Genet. 10, 32–42 (2009).
Brownell, J. E. & Allis, C. D. Special HATs for special occasions: linking histone acetylation to chromatin assembly and gene activation. Curr. Opin. Genet. Dev. 6, 176–184 (1996).
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007).
Li, B., Carey, M. & Workman, J. L. The role of chromatin during transcription. Cell 128, 707–719 (2007).
Shahbazian, M. D. & Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75–100 (2007).
Tweedie-Cullen, R. Y. et al. Identification of combinatorial patterns of post-translational modifications on individual histones in the mouse brain. PLoS ONE 7, e36980 (2012). The first study to comprehensively map all existing post-translational histone modifications in the mouse brain by mass spectrometry.
Miller, C. A., Campbell, S. L. & Sweatt, J. D. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol. Learn. Mem. 89, 599–603 (2008).
Gräff, J. & Mansuy, I. M. Epigenetic codes in cognition and behaviour. Behav. Brain Res. 192, 70–87 (2008).
Koshibu, K. et al. Protein phosphatase 1 regulates the histone code for long-term memory. J. Neurosci. 29, 13079–13089 (2009).
Koshibu, K., Graff, J. & Mansuy, I. M. Nuclear protein phosphatase-1: an epigenetic regulator of fear memory and amygdala long-term potentiation. Neuroscience 173, 30–36 (2011).
Gräff, J., Woldemichael, B. T., Berchtold, D., Dewarrat, G. & Mansuy, I. M. Dynamic histone marks in the hippocampus and cortex facilitate memory consolidation. Nature Commun. 3, 991 (2012). The first study to show that post-translational histone modifications accompany the spatiotemporal dynamics of memory consolidation.
Maharana, C., Sharma, K. P. & Sharma, S. K. Depolarization induces acetylation of histone H2B in the hippocampus. Neuroscience 167, 354–360 (2010).
Crosio, C., Heitz, E., Allis, C. D., Borrelli, E. & Sassone-Corsi, P. Chromatin remodeling and neuronal response: multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons. J. Cell Sci. 116, 4905–4914 (2003).
Sweatt, J. D. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 76, 1–10 (2001).
Levenson, J. M. et al. Regulation of histone acetylation during memory formation in the hippocampus. J. Biol. Chem. 279, 40545–40559 (2004). A ground-breaking study showing that learning itself triggers histone acetylation changes in the mammalian brain.
Latham, J. A. & Dent, S. Y. Cross-regulation of histone modifications. Nature Struct. Mol. Biol. 14, 1 017–1024 (2007). An excellent review about the crosstalks between post-translational histone modifications.
Cowansage, K. K., LeDoux, J. E. & Monfils, M. H. Brain-derived neurotrophic factor: a dynamic gatekeeper of neural plasticity. Curr. Mol. Pharmacol. 3, 12–29 (2010).
Nott, A., Watson, P. M., Robinson, J. D., Crepaldi, L. & Riccio, A. S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 455, 411–415 (2008). An important paper showing the upstream regulatory mechanisms of HDAC2 following neuronal activity.
Chen, W. G. et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science 302, 885–889 (2003).
Guan, J. S. et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459, 55–60 (2009). A tour-de-force study in which the first HDAC to have a pivotal role in neuroplasticity was identified.
Pittenger, C. & Kandel, E. R. In search of general mechanisms for long-lasting plasticity: Aplysia and the hippocampus. Phil. Trans. R. Soc. Lond. B 358, 757–763 (2003).
Guan, Z. H. et al. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111, 483–493 (2002).
Hart, A. K. et al. Serotonin-mediated synapsin expression is necessary for long-term facilitation of the Aplysia sensorimotor synapse. J. Neurosci. 31, 18401–18411 (2011).
Bliss, T. V. & Collingridge, G. L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31–39 (1993).
Miller, C. A. & Sweatt, J. D. Covalent modification of DNA regulates memory formation. Neuron 53, 857–869 (2007).
Vecsey, C. G. et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci. 27, 6128–6140 (2007).
Zeng, Y. et al. Epigenetic enhancement of BDNF signaling rescues synaptic plasticity in aging. J. Neurosci. 31, 17800–17810 (2011).
Yeh, S. H., Lin, C. H. & Gean, P. W. Acetylation of nuclear factor-κB in rat amygdala improves long-term but not short-term retention of fear memory. Mol. Pharmacol. 65, 1286–1292 (2004).
Sui, L., Wang, Y., Ju, L. H. & Chen, M. Epigenetic regulation of reelin and brain-derived neurotrophic factor genes in long-term potentiation in rat medial prefrontal cortex. Neurobiol. Learn. Mem. 97, 425–440 (2012).
Alarcon, J. M. et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/− mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42, 947–959 (2004). Together with reference 64, these two papers provided the first causal evidence that (CBP-mediated) histone acetylation is necessary for long-term memory and plasticity.
Barrett, R. M. et al. Hippocampal focal knockout of CBP affects specific histone modifications, long-term potentiation, and long-term memory. Neuropsychopharmacology 36, 1545–1556 (2011).
Wood, M. A. et al. Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn. Mem. 12, 111–119 (2005).
Chwang, W. B., Arthur, J. S., Schumacher, A. & Sweatt, J. D. The nuclear kinase mitogen- and stress-activated protein kinase 1 regulates hippocampal chromatin remodeling in memory formation. J. Neurosci. 27, 12732–12742 (2007).
Chwang, W. B., O'Riordan, K. J., Levenson, J. M. & Sweatt, J. D. ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn. Mem. 13, 322–328 (2006).
Lubin, F. D., Roth, T. L. & Sweatt, J. D. Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory. J. Neurosci. 28, 10576–10586 (2008).
Maddox, S. A. & Schafe, G. E. Epigenetic alterations in the lateral amygdala are required for reconsolidation of a Pavlovian fear memory. Learn. Mem. 18, 579–593 (2011).
Monsey, M. S., Ota, K. T., Akingbade, I. F., Hong, E. S. & Schafe, G. E. Epigenetic alterations are critical for fear memory consolidation and synaptic plasticity in the lateral amygdala. PLoS ONE 6, e19958 (2011).
Bousiges, O. et al. Spatial memory consolidation is associated with induction of several lysine-acetyltransferase (histone acetyltransferase) expression levels and H2B/H4 acetylation-dependent transcriptional events in the rat hippocampus. Neuropsychopharmacology 35, 2521–2537 (2010).
Fontan-Lozano, A. et al. Histone deacetylase inhibitors improve learning consolidation in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice. Mol. Cell. Neurosci. 39, 193–201 (2008).
Lesburgueres, E. et al. Early tagging of cortical networks is required for the formation of enduring associative memory. Science 331, 924–928 (2011).
Reul, J. M., Hesketh, S. A., Collins, A. & Mecinas, M. G. Epigenetic mechanisms in the dentate gyrus act as a molecular switch in hippocampus-associated memory formation. Epigenetics 4, 434–439 (2009).
Bredy, T. W. & Barad, M. The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn. Mem. 15, 39–45 (2008).
Bredy, T. W. et al. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn. Mem. 14, 268–276 (2007).
Lattal, K. M., Barrett, R. M. & Wood, M. A. Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. Behav. Neurosci. 121, 1125–1131 (2007).
Itzhak, Y., Anderson, K. L., Kelley, J. B. & Petkov, M. Histone acetylation rescues contextual fear conditioning in nNOS KO mice and accelerates extinction of cued fear conditioning in wild type mice. Neurobiol. Learn. Mem. 97, 409–417 (2012).
Stafford, J. M., Raybuck, J. D., Ryabinin, A. E. & Lattal, K. M. Increasing histone acetylation in the hippocampus-infralimbic network enhances fear extinction. Biol. Psychiatry 72, 25–33 (2012).
Federman, N., Fustinana, M. S. & Romano, A. Reconsolidation involves histone acetylation depending on the strength of the memory. Neuroscience 219, 145–156 (2012).
Danilova, A. B., Kharchenko, O. A., Shevchenko, K. G. & Grinkevich, L. N. Histone H3 acetylation is asymmetrically induced upon learning in identified neurons of the food aversion network in the mollusk helix lucorum. Front. Behav. Neurosci. 4, 180 (2010).
Federman, N., Fustinana, M. S. & Romano, A. Histone acetylation is recruited in consolidation as a molecular feature of stronger memories. Learn. Mem. 16, 600–606 (2009).
Lubin, F. D. & Sweatt, J. D. The IκB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron 55, 942–957 (2007).
Fischer, A., Sananbenesi, F., Wang, X. Y., Dobbin, M. & Tsai, L. H. Recovery of learning and memory is associated with chromatin remodelling. Nature 447, 178–182 (2007). An important study showing, for the first time, that cognitive capacities can be rescued despite severe neurodegeneration by the use of an HDACi.
Hawk, J. D., Florian, C. & Abel, T. Post-training intrahippocampal inhibition of class I histone deacetylases enhances long-term object-location memory. Learn. Mem. 18, 367–370 (2011).
McQuown, S. C. et al. HDAC3 is a critical negative regulator of long-term memory formation. J. Neurosci. 31, 764–774 (2011).
Murphy, K. J. et al. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J. Neurochem. 78, 704–714 (2001).
O'Loinsigh, E. D. et al. Differential enantioselective effects of pentyl-4-yn-valproate on spatial learning in the rat, and neurite outgrowth and cyclin D3 expression in vitro. J. Neurochem. 88, 370–379 (2004).
Stefanko, D. P., Barrett, R. M., Ly, A. R., Reolon, G. K. & Wood, M. A. Modulation of long-term memory for object recognition via HDAC inhibition. Proc. Natl Acad. Sci. USA 106, 9447–9452 (2009).
Zhao, Z., Fan, L. & Frick, K. M. Epigenetic alterations regulate estradiol-induced enhancement of memory consolidation. Proc. Natl Acad. Sci. USA 107, 5605–5610 (2010).
Korzus, E., Rosenfeld, M. G. & Mayford, M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 42, 961–972 (2004).
Oike, Y. et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum. Mol. Genet. 8, 387–396 (1999).
Oliveira, A. M. M., Wood, M. A. & McDonough, C. B. & Abel, T. Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn. Mem. 14, 564–572 (2007).
Wood, M. A., Attner, M. A., Oliveira, A. M., Brindle, P. K. & Abel, T. A transcription factor-binding domain of the coactivator CBP is essential for long-term memory and the expression of specific target genes. Learn. Mem. 13, 609–617 (2006).
Scandura, J. M. et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118, 1472–1480 (2011).
Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361–6369 (2006).
Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A. & Chandra, J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J. Biomed. Biotechnol. 2011, 514261 (2011).
Bordone, L. & Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nature Rev. Mol. Cell Biol. 6, 298–305 (2005).
Haigis, M. C. & Sinclair, D. A. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5, 253–295 (2010).
Chen, J. et al. SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling. J. Biol. Chem. 280, 40364–40374 (2005).
Kim, D. et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169–3179 (2007).
Michan, S. et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci. 30, 9695–9707 (2010).
Gao, J. et al. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466, 1105–1109 (2010).
Broide, R. S. et al. Distribution of histone deacetylases 1–11 in the rat brain. J. Mol. Neurosci. 31, 47–58 (2007).
Nelson, E. D., Bal, M., Kavalali, E. T. & Monteggia, L. M. Selective impact of MeCP2 and associated histone deacetylases on the dynamics of evoked excitatory neurotransmission. J. Neurophysiol. 106, 193–201 (2011).
Gupta-Agarwal, S. et al. G9a/GLP histone lysine dimethyltransferase complex activity in the hippocampus and the entorhinal cortex is required for gene activation and silencing during memory consolidation. J. Neurosci. 32, 5440–5453 (2012). A valuable resource for microarray-deduced hippocampal gene expression changes following contextual fear conditioning.
Kim, D. et al. Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron 60, 803–817 (2008).
Herrup, K. & Yang, Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology? Nature Rev. Neurosci. 8, 368–378 (2007).
Bahari-Javan, S. et al. HDAC1 regulates fear extinction in mice. J. Neurosci. 32, 5062–5073 (2012).
Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 104, 17335–17340 (2007).
Wang, W. H. et al. Intracellular trafficking of histone deacetylase 4 regulates long-term memory formation. Anat. Rec. 294, 1025–1034 (2011).
Kim, M. S. et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J. Neurosci. 32, 10879–10886 (2012).
Koseki, T. et al. Exposure to enriched environments during adolescence prevents abnormal behaviours associated with histone deacetylation in phencyclidine-treated mice. Int J. Neuropsychopharmacol. 15, 1489–1450 (2011).
Tam, G. W. et al. Confirmed rare copy number variants implicate novel genes in schizophrenia. Biochem. Soc. Trans. 38, 445–451 (2010).
Citron, M. Alzheimer's disease: strategies for disease modification. Nature Rev. Drug Discov. 9, 387–398 (2010). A comprehensive overview of the challenges and strategies in AD research.
Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204–1222 (2012).
Gräff, J. et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483, 222–226 (2012). The first study to causally implicate an HDAC, HDAC2, in cognitive decline associated with neurodegeneration.
Cruz, J. C. et al. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J. Neurosci. 26, 10536–10541 (2006).
Cruz, J. C., Tseng, H. C., Goldman, J. A., Shih, H. & Tsai, L. H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471–483 (2003).
Fischer, A., Sananbenesi, F., Pang, P. T., Lu, B. & Tsai, L. H. Opposing roles of transient and prolonged expression of p25 in synaptic plasticity and hippocampus-dependent memory. Neuron 48, 825–838 (2005).
Kimura, R. & Ohno, M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 33, 229–235 (2009).
Oakley, H. et al. Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129–10140 (2006).
Frankland, P. W. & Bontempi, B. The organization of recent and remote memories. Nature Rev. Neurosci. 6, 119–130 (2005).
Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259 (1991).
Holtzman, D. M., Morris, J. C. & Goate, A. M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3, 77sr71 (2011).
Crapper, D. R., Quittkat, S. & de Boni, U. Altered chromatin conformation in Alzheimer's disease. Brain 102, 483–495 (1979). Together with reference 100, this early report hints at the intriguing possibility of increased heterochromatinization in the AD brain.
Lukiw, W. J. & Crapper McLachlan, D. R. Chromatin structure and gene expression in Alzheimer's disease. Brain Res. Mol. Brain Res. 7, 227–233 (1990).
Magistretti, P. J. Neuroscience. Low-cost travel in neurons. Science 325, 1349–1351 (2009).
Mery, F. & Kawecki, T. J. A cost of long-term memory in Drosophila. Science 308, 1148 (2005). An intriguing report documenting a trade-off between memory and lifespan under certain (stressful) conditions.
Laughlin, S. B. Energy as a constraint on the coding and processing of sensory information. Curr. Opin. Neurobiol. 11, 475–480 (2001).
Laughlin, S. B., de Ruyter van Steveninck, R. R. & Anderson, J. C. The metabolic cost of neural information. Nature Neurosci. 1, 36–41 (1998).
Bishop, N. A., Lu, T. & Yankner, B. A. Neural mechanisms of ageing and cognitive decline. Nature 464, 529–535 (2010).
Ricobaraza, A. et al. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34, 1721–1732 (2009).
Francis, Y. I. et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J. Alzheimers Dis. 18, 131–139 (2009).
Govindarajan, N., Agis-Balboa, R. C., Walter, J., Sananbenesi, F. & Fischer, A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J. Alzheimers Dis. 26, 187–197 (2011).
Walker, M. P., Laferla, F. M., Oddo, S. S. & Brewer, G. J. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. Age 12 Jan 2012 (doi:10.1007/s11357-011-9375-5).
Mastroeni, D. et al. Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiol. Aging 31, 2025–2037 (2010).
Blalock, E. M. et al. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J. Neurosci. 23, 3807–3819 (2003).
Lee, C. K., Weindruch, R. & Prolla, T. A. Gene-expression profile of the ageing brain in mice. Nature Genet. 25, 294–297 (2000).
Loerch, P. M. et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS ONE 3, e3329 (2008).
Lu, T. et al. Gene regulation and DNA damage in the ageing human brain. Nature 429, 883–891 (2004).
Peleg, S. et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328, 753–756 (2010).
Tang, B., Dean, B. & Thomas, E. A. Disease- and age-related changes in histone acetylation at gene promoters in psychiatric disorders. Transl. Psychiatry 1, e64 (2011).
Ryu, S. H., Kang, K., Yoo, T., Joe, C. O. & Chung, J. H. Transcriptional repression of repeat-derived transcripts correlates with histone hypoacetylation at repetitive DNA elements in aged mice brain. Exp. Gerontol. 46, 811–818 (2011).
Borrell-Pages, M., Zala, D., Humbert, S. & Saudou, F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63, 2642–2660 (2006).
Garber, K. B., Visootsak, J. & Warren, S. T. Fragile X syndrome. Eur. J. Hum. Genet. 16, 666–672 (2008).
Hunter, R. G. et al. Acute stress and hippocampal histone H3 lysine 9 trimethylation, a retrotransposon silencing response. Proc. Natl Acad. Sci. USA 109, 17657–17662 (2012).
Kang, J. E., Cirrito, J. R., Dong, H., Csernansky, J. G. & Holtzman, D. M. Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity. Proc. Natl Acad. Sci. USA 104, 10673–10678 (2007).
Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L. & LaFerla, F. M. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer's disease. J. Neurosci. 26, 9047–9056 (2006).
Porter, N. M. & Landfield, P. W. Stress hormones and brain aging: adding injury to insult? Nature Neurosci. 1, 3–4 (1998).
Lupien, S. J. et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neurosci. 1, 69–73 (1998).
Oztan, O., Aydin, C. & Isgor, C. Stressful environmental and social stimulation in adolescence causes antidepressant-like effects associated with epigenetic induction of the hippocampal BDNF and mossy fibre sprouting in the novelty-seeking phenotype. Neurosci. Lett. 501, 107–111 (2011).
Levine, A., Worrell, T. R., Zimnisky, R. & Schmauss, C. Early life stress triggers sustained changes in histone deacetylase expression and histone H4 modifications that alter responsiveness to adolescent antidepressant treatment. Neurobiol. Dis. 45, 488–498 (2012).
Sananbenesi, F. & Fischer, A. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol. Chem. 390, 1145–1153 (2009).
McQuown, S. C. & Wood, M. A. HDAC3 and the molecular brake pad hypothesis. Neurobiol. Learn. Mem. 96, 27–34 (2011).
Brunmeir, R., Lagger, S. & Seiser, C. Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. Int. J. Dev. Biol. 53, 275–289 (2009).
Fischer, A., Sananbenesi, F., Mungenast, A. & Tsai, L. H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 31, 605–617 (2010).
Haggarty, S. J. & Tsai, L. H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol. Learn. Mem. 96, 41–52 (2011).
Kwon, P., Hsu, M., Cohen, D. & Atadja, P. in Histone Deacetylases: Transcriptional Regulation and Other Cellular Functions (ed. Verdin, E.) 315–332 (Humana Press, 2006).
Kilgore, M. et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35, 870–880 (2009).
Ricobaraza, A., Cuadrado-Tejedor, M. & Garcia-Osta, A. Long-term phenylbutyrate administration prevents memory deficits in Tg2576 mice by decreasing Aβ. Front. Biosci. 3, 1375–1384 (2011).
Ricobaraza, A., Cuadrado-Tejedor, M., Marco, S., Perez-Otano, I. & Garcia-Osta, A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22, 1040–1050 (2012).
Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041–2046 (2003).
Thomas, E. A. et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA 105, 15564–15569 (2008).
Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418–9427 (2003).
Gardian, G. et al. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J. Biol. Chem. 280, 556–563 (2005).
Sadri-Vakili, G. et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum. Mol. Genet. 16, 1293–1306 (2007).
Petri, S. et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22, 40–49 (2006).
Rouaux, C. et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J. Neurosci. 27, 5535–5545 (2007).
Rossetti, F. et al. Combined diazepam and HDAC inhibitor treatment protects against seizures and neuronal damage caused by soman exposure. Neurotoxicology 33, 500–511 (2012).
Reolon, G. K. et al. Posttraining systemic administration of the histone deacetylase inhibitor sodium butyrate ameliorates aging-related memory decline in rats. Behav. Brain Res. 221, 329–332 (2011).
Weaver, I. C. G. et al. Epigenetic programming by maternal behavior. Nature Neurosci. 7, 847–854 (2004). A highly influential report showing that early-life stress can trigger lasting epigenetic modifications that influence behaviour later in life in rats. This finding was later replicated in humans (see reference 168).
Kim, H. S. et al. Inhibition of histone deacetylation enhances the neurotoxicity induced by the C-terminal fragments of amyloid precursor protein. J. Neurosci. Res. 75, 117–124 (2004).
Salminen, A., Tapiola, T., Korhonen, P. & Suuronen, T. Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res. Mol. Brain Res. 61, 203–206 (1998).
Khan, O. & La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85–94 (2012).
Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nature Rev. Genet. 10, 295–304 (2009).
Scott, G. K., Mattie, M. D., Berger, C. E., Benz, S. C. & Benz, C. C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 66, 1277–1281 (2006).
Tsankova, N., Renthal, W., Kumar, A. & Nestler, E. J. Epigenetic regulation in psychiatric disorders. Nature Rev. Neurosci. 8, 355–367 (2007).
Gräff, J. & Mansuy, I. M. Epigenetic dysregulation in cognitive disorders. Eur. J. Neurosci. 30, 1–8 (2009).
Haettig, J. et al. HDAC inhibition modulates hippocampus-dependent long-term memory for object location in a CBP-dependent manner. Learn. Mem. 18, 71–79 (2011).
Malvaez, M., Sanchis-Segura, C., Vo, D., Lattal, K. M. & Wood, M. A. Modulation of chromatin modification facilitates extinction of cocaine-induced conditioned place preference. Biol. Psychiatry 67, 36–43 (2010).
Covington, H. E., 3rd et al. Antidepressant actions of histone deacetylase inhibitors. J. Neurosci. 29, 11451–11460 (2009).
Schroeder, F. A., Lin, C. L., Crusio, W. E. & Akbarian, S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol. Psychiatry 62, 55–64 (2007).
Tsankova, N. M. et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nature Neurosci. 9, 519–525 (2006).
Kurita, M. et al. HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neurosci. 15, 1245–1254 (2012).
Mims, A. & Marcucci, G. Epigenetic priming: the target? Blood 118, 1430–1431 (2011).
Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome — biological and translational implications. Nature Rev. Cancer 11, 726–734 (2011).
Bangert, A., Hacker, S., Cristofanon, S., Debatin, K. M. & Fulda, S. Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275. Anticancer Drugs 22, 494–499 (2011).
Marchion, D. C. et al. HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol. Cancer Ther. 8, 794–801 (2009).
Milekic, M. H. & Alberini, C. M. Temporally graded requirement for protein synthesis following memory reactivation. Neuron 36, 521–525 (2002).
Naqib, F., Sossin, W. Y. & Farah, C. A. Molecular determinants of the spacing effect. Neural Plast. 2012, 581291 (2012).
Kriaucionis, S. & Heintz, N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324, 929–930 (2009).
Liu, B. L. et al. Global histone modification patterns as prognostic markers to classify glioma patients. Cancer Epidemiol. Biomarkers Prev. 19, 2888–2896 (2010).
Lee, Y. S. & Silva, A. J. The molecular and cellular biology of enhanced cognition. Nature Rev. Neurosci. 10, 126–140 (2009).
McGowan, P. O. et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neurosci. 12, 342–348 (2009).
Basha, M. R. et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and β-amyloid in the aging brain. J. Neurosci. 25, 823–829 (2005).
Wu, J. et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J. Neurosci. 28, 3–9 (2008).
Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).
Lahiri, D. K., Maloney, B. & Zawia, N. H. The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases. Mol. Psychiatry 14, 992–1003 (2009). An intriguing review positing that early-life events might epigenetically influence cognitive health later in life.
Bihaqi, S. W., Huang, H., Wu, J. & Zawia, N. H. Infant exposure to lead (Pb) and epigenetic modifications in the aging primate brain: implications for Alzheimer's disease. J. Alzheimers Dis. 27, 819–833 (2011).
Halagappa, V. K. et al. Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the triple-transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 26, 212–220 (2007).
Qin, W. et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281, 21745–21754 (2006).
Wang, J. et al. Caloric restriction attenuates β-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 19, 659–661 (2005).
Witte, A. V., Fobker, M., Gellner, R., Knecht, S. & Floel, A. Caloric restriction improves memory in elderly humans. Proc. Natl Acad. Sci. USA 106, 1255–1260 (2009).
Funato, H., Oda, S., Yokofujita, J., Igarashi, H. & Kuroda, M. Fasting and high-fat diet alter histone deacetylase expression in the medial hypothalamus. PLoS ONE 6, e18950 (2011).
Valor, L. M. et al. Ablation of CBP in forebrain principal neurons causes modest memory and transcriptional defects and a dramatic reduction of histone acetylation but does not affect cell viability. J. Neurosci. 31, 1652–1663 (2011).
Brunner, A. M., Tweedie-Cullen, R. Y. & Mansuy, I. M. Epigenetic modifications of the neuroproteome. Proteomics 12, 2404–2420 (2012).
We thank S. Jemielity and A. Mungenast for critical reading of the manuscript and acknowledge support from a Bard Richmond grant to J.G., and the US National Institutes of Health (grants, NS078839 and NS51874) to L.-H.T. L.-H.T. is an investigator of the Howard Hughes Medical Institute.
The authors declare no competing financial interests.
- Histone proteins
Basic proteins with a globular core and loosely structured N- and C-terminal tails that form part of the chromatin. Doublets of the four core histones H2A, H2B, H3 and H4 constitute a histone octamer, which is wrapped around by DNA to form the nucleosome. Post-translational histone modifications modulate the compaction of the DNA around histones and thereby the three-dimensional chromatin structure.
- Histone deacetylase inhibitors
(HDACis). Small molecules that inhibit the activity of HDACs, most of them by binding to the HDAC catalytic domain.
- Synaptic plasticity
The ability of a synapse to change in strength, which is considered to be a cellular correlate of learning and memory.
- Long-term facilitation
(LTF). Transcription-dependent facilitation of electrical transmission across synapses.
- Long-term depression
(LTD). Transcription-dependent deterioration of electrical transmission across synapses.
- Long-term potentiation
(LTP). An increase in synaptic transmission efficiency as a result of presynaptic high-frequency stimulation.
- Fear conditioning
A form of associative learning in which an aversive stimulus (for example, an electric shock) is paired with a neutral context (for example, a chamber) or neutral stimulus (for example, a tone), resulting in the expression of fear responses to the originally neutral context or stimulus in the absence of the aversive stimulus.
- Latent inhibition
A decrease of the conditioned response in an associative memory task when the conditioned stimulus is presented alone before the conditioning session.
A time-limited process that allows newly acquired memories to be stabilized and permanently stored.
A time-limited process that allows reactivated memories to be updated with new information and to be stored in a modified form.
- Object location memory
Memory for an object's location that is measured by taking advantage of rodents' natural propensity to explore novel objects. The time spent with a novel versus a familiar object serves as an indicator of the memory strength. In object location, the novelty is given by a change in location of a familiar object.
- Object recognition memory
The ability to recognize an object as familiar rather than novel. It is measured in a similar way to object location memory but with the novelty given by presenting the animal with an object that is unfamiliar but in the same location..
- Fear memory extinction
A decline in conditioned fear responses when there is a reduction in the predictive value of the conditioned stimulus, for example, through repetitive exposure to the conditioned stimulus without the aversive association.
- Alzheimer's disease
(AD). The most common type of neurodegenerative dementia. Patients often show impairments in learning and memory. The disease's neuropathology includes neuron loss in the cerebral cortex and in several subcortical regions and the presence of aggregates in the forms of plaques (containing amyloid-β) and neurofibrillary tangles (containing hyperphosphorylated tau).
- Braak and Braak stages
A way to categorize the severity of Alzheimer's disease (AD) according to the extent of tau pathology post-mortem. In BB stages I/II (mild AD), tau pathology is mainly restricted to the entorhinal cortex. In stages III/IV (moderate AD), tau pathology has spread to the hippocampal formation and subcortical nuclei. In stages V/VI (severe AD), tau pathology affects the entire brain.
- Huntington's disease
(HD). A neurodegenerative disease that is characterized by progressive loss of movement coordination, muscular atrophy and cognitive decline. It is caused by mutations in the huntingtin gene that lead to abnormally high repetitions of the triplet CAG at its 5′-coding region.
- Fragile X syndrome
A common form of neurodevelopmental mental retardation caused by unusual trinucleotide expansions and subsequent gene silencing of fragile X mental retardation 1 (FMR1) or FMR2.
- Amyotrophic lateral sclerosis
(ALS). A progressive neurological disease that is associated with the degeneration of central and spinal motor neurons. This neuron loss causes muscles to weaken, leading to paralysis. About 90% of all ALS cases are sporadic, the remaining 10% being caused by genetic mutations, for example, in superoxide dismutase 1 (SOD1).
- Rubinstein–Taybi syndrome
A monogenic neurodevelopmental disorder caused by mutations in the gene coding for the histone acetyltransferase cyclic AMP-responsive element-binding (CREB)-binding protein (CBP). The disease is characterized by skeletal and facial abnormalities, and varying degrees of mental retardation.
About this article
Cite this article
Gräff, J., Tsai, LH. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci 14, 97–111 (2013). https://doi.org/10.1038/nrn3427
Cross talk between acetylation and methylation regulators reveals histone modifier expression patterns posing prognostic and therapeutic implications on patients with colon cancer
Clinical Epigenetics (2022)
Adverse maternal environment affects hippocampal HTR2c variant expression and epigenetic characteristics in mouse offspring
Pediatric Research (2022)
Cell Death & Differentiation (2022)
The ketogenic diet increases Neuregulin 1 expression via elevating histone acetylation and its anti-seizure effect requires ErbB4 kinase activity
Cell & Bioscience (2021)
Pre-treatment clinical and gene expression patterns predict developmental change in early intervention in autism
Molecular Psychiatry (2021)